Early Safety Monitoring of COVID-19 Vaccines in Healthcare Workers
10.3346/jkms.2021.36.e110
- Author:
Joon Young SONG
1
;
Hee Jin CHEONG
;
Sung Ran KIM
;
Sung Eun LEE
;
Su Hyun KIM
;
Ji Yun NOH
;
Young Kyung YOON
;
Won Suk CHOI
;
Dae Won PARK
;
Jang Wook SOHN
;
Woo Joo KIM
;
Min Ja KIM
Author Information
1. Division of Infectious Diseases, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea
- Publication Type:Brief Communication
- From:Journal of Korean Medical Science
2021;36(15):e110-
- CountryRepublic of Korea
- Language:English
-
Abstract:
Hospital-based surveillance for adverse events was conducted on healthcare workers after they received the first dose of coronavirus disease 2019 (COVID-19) vaccine. Among the two new platform vaccines (messenger RNA- and adenoviral vector-based vaccines), the rates of systemic adverse events were significantly higher among adenovirus-vectored vaccine recipients. Fatigue (87.6% vs. 53.8%), myalgia (80.8% vs. 50.0%), headache (72.0% vs.28.8%), and fever (≥ 38.0°C, 38.7% vs. 0%) were the most common adverse events among adenovirus-vectored vaccine recipients, but most symptoms resolved within 2 days. Both types of COVID-19 vaccines were generally safe, and serious adverse events rarely occurred.
